This invention is in the area of biologically active nucleosides, and specifically includes a method for the resolution of nucleoside enantiomers, including 1,3-oxathiolane nucleosides, and antiviral compositions that include the enantiomerically enriched 1,3-oxathiolane nucleosides, (xe2x88x92) and (+)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (xe2x80x9cFTCxe2x80x9d).
This application is a continuation-in-part application of U.S. Ser. No. 07/659,760, entitled xe2x80x9cMethod for the Synthesis, Compositions and Use of 2xe2x80x2-Deoxy-5-Fluoro-3xe2x80x2-Thiacytidine and Related Compoundsxe2x80x9d, filed on Feb. 22, 1991, by Dennis C. Liotta, Raymond Schinazi, and Woo-Baeg Choi, that is a continuation-in-part application of U.S. Ser. No. 07/473,318, entitled xe2x80x9cMethod and Compositions for the Synthesis of BCH-189 and Related Compounds,xe2x80x9d filed on Feb. 1, 1990, by Dennis C. Liotta and Woo-Baeg Choi.
In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that almost without exception leads to death. In 1983, the etiological cause of AIDS was determined to be the human immunodeficiency virus (HIV). In December, 1990, the World Health Organization estimated that between 8 and 10 million people worldwide were infected with HIV, and of that number, between 1,000,000 and 1,400,000 were in the U.S.
In 1985, it was reported that the synthetic nucleoside 3xe2x80x2-azido-3xe2x80x2-deoxythymidine (AZT) inhibits the replication of human immunodeficiency virus type 1. Since then, a number of other synthetic nucleosides, including 2xe2x80x2,3xe2x80x2-dideoxyinosine (DDI), 2xe2x80x2,3xe2x80x2-dideoxycytidine (DDC), 3xe2x80x2-fluoro-3xe2x80x2-deoxythymidine (FLT), 2xe2x80x2,3xe2x80x2-dideoxy-2xe2x80x2,3xe2x80x2-didehydrothymidine (D4T), and 3xe2x80x2-azido-2xe2x80x2,3xe2x80x2-dideoxyuridine (AZDU), have been proven to be effective against HIV. A number of other 2xe2x80x2,3xe2x80x2-dideoxynucleosides have been demonstrated to inhibit the growth of a variety of other viruses in vitro. It appears that, after cellular phosphorylation to the 5xe2x80x2-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination due to the absence of the 3xe2x80x2-hydroxyl group.
In its triphosphate form, 3xe2x80x2-azido-3xe2x80x2-deoxythymidine is a potent inhibitor of HIV reverse transcriptase and has been approved by the FDA for the treatment of AIDS. However, the benefits of AZT must be weighed against the severe adverse reactions of bone marrow suppression, nausea, myalgia, insomnia, severe headaches, anemia, peripheral neuropathy, and seizures. These adverse side effects often occur immediately after treatment begins, whereas a minimum of six weeks of therapy is necessary to realize AZT""s benefits. DDI, which has recently been approved by an FDA Committee for the treatment of AIDS, is also associated with a number of side effects, including sporadic pancreatis and peripheral neuropathy.
Both DDC and D4T are potent inhibitors of HIV replication with activities comparable (D4T) or superior (DDC) to AZT. However, both DDC and D4T are not efficiently converted to the corresponding 5xe2x80x2-triphosphates in vivo. Both compounds are also toxic and can cause peripheral neuropathies in humans.
The success of various 2xe2x80x2,3xe2x80x2-dideoxynucleosides in inhibiting the replication of HIV in vivo or in vitro has led a number of researchers to design and test nucleosides that substitute a heteroatom for the carbon atom at the 3xe2x80x2-position of the nucleoside. Norbeck, et al., disclose that (xc2x1)-1-[(2xcex2,4xcex2)-2-(hydroxymethyl)-4-dioxolanyl]thymine (referred to below as (xc2x1)-dioxolane-T) exhibits a modest activity against HIV (EC50 of 20 xcexcm in ATH8 cells), and is not toxic to uninfected control cells at a concentration of 200 xcexcm. Tetrahedron Letters 30 (46), 6246, (1989).
European Patent Application Publication No. 0 382 526 filed by IAF Biochem International, Inc. discloses a number of substituted 1,3-oxathiolanes with antiviral activity, and specifically reports that the racemic mixture (about the C4xe2x80x2-position) of the C1xe2x80x2-xcex2 isomer of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (referred to below as (xc2x1)-BCH-189) has approximately the same activity against HIV as AZT, and no cellular toxicity at therapeutic levels. (xc2x1)-BCH-189 has also been found to inhibit the replication of AZT-resistant, HIV isolates from patients who have been treated with AZT for longer than 36 weeks.
To market a nucleoside for pharmaceutical purposes, it must not only be efficacious with low toxicity, it must also be cost effective to manufacture. An extensive amount of research and development has been directed toward new, low cost processes for large scale nucleoside production. 2xe2x80x2,3xe2x80x2-Dideoxynucleosides are currently prepared by either of two routes: derivatization of an intact nucleoside or condensation of a derivatized sugar moiety with a heterocyclic base. Although there are numerous disadvantages associated with obtaining new nucleoside analogues by modifying intact nucleosides, a major advantage of this approach is that the appropriate absolute stereochemistry has already been set by nature. However, this approach cannot be used in the production of nucleosides that contain either nonnaturally occurring bases or nonnaturally occurring carbohydrate moieties (and which therefore are not prepared from intact nucleosides), such as 1,3-oxathiolane nucleosides and 1,3-dioxolane nucleosides.
When condensing a carbohydrate or carbohydrate-like moiety with a heterocyclic base to form a synthetic nucleoside, a nucleoside is produced that has two chiral centers (at the C1xe2x80x2 and C4xe2x80x2-positions), and thus exists as a diasteromeric pair. Each diastereomer exists as a set of enantiomers. Therefore, the product is a mixture of four enantiomers.
It is often found that nucleosides with nonnaturally-occurring stereochemistry in either the C1xe2x80x2 or the C4xe2x80x2-positions are less active than the same nucleoside with the stereochemistry as set by nature. For example, Carter, et al., have reported that the concentration of the (xe2x88x92)-enantiomer of carbovir (2xe2x80x2,3xe2x80x2-didehydro-2xe2x80x2,3xe2x80x2-dideoxyguanosine) required to reduce the reverse transcriptase activity by 50% (EC50 ) is 0.8 xcexcM, whereas the EC50 for the (+)-enantiomer of carbovir is greater than 60 xcexcM. Antimicrobial Agents and Chemotherapy, 34:6, 1297-1300 (June 1990).
U.S. Ser. No. 07/659,760 discloses that 1,3-oxathiolane and 1,3-dioxolane nucleosides can be prepared with high diastereoselectivity (high percentage of nucleoside with a xcex2 configuration of the bond from the C1xe2x80x2-carbon to the heterocyclic base) by careful selection of the Lewis acid used in the condensation process. It was discovered that condensation of a 1,3-oxathiolane nucleoside with a base occurs with almost complete xcex2-stereospecificity when stannic chloride is used as the condensation catalyst, and condensation of 1,3-dioxolane with a base occurs with almost complete xcex2-stereospecificity when various chlorotitanium catalysts are employed. Other Lewis acids provide low (or no) C1xe2x80x2-xcex2 selectivity or simply fail to catalyze the reactions.
There remains a strong need to provide a cost effective, commercially viable method to obtain xcex2-stereospecificity of synthetic nucleosides prepared by condensing a carbohydrate-like moiety with a base. This is important because it is likely that many synthetic nucleoside inhibitors of viral replication now emerging from academic and commercial laboratories will require resolution. An economical and facile method for resolving racemic mixtures of nucleosides would greatly facilitate antiviral research and ultimately, commercial manufacture. Further, resolution of racemic mixtures of nucleosides may provide a route to increase the activity of synthetic nucleosides by eliminating or minimizing the undesired enantiomer.
Therefore, it is an object of the present invention to provide a method for the resolution of racemic mixtures of nucleosides.
It is another object of the present invention to provide enantiomerically enriched 1,3-oxathiolane nucleosides.
It is still another object of the present invention to provide enantiomerically enriched 1,3-oxathiolane nucleosides with significant antiviral activity and low toxicity.
A process for the resolution of a racemic mixture of nucleoside enantiomers or their derivatives is disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The process can be used to resolve a wide variety of nucleosides, including pyrimidine and purine nucleosides that are optionally substituted in the carbohydrate moiety or base moiety. The process can also be used to resolve nucleoside derivatives that contain additional heteroatoms in the carbohydrate moiety, for example, FTC and BCH-189. The resolution of nucleosides can be performed on large scale at moderate cost.
It has been discovered that the nucleoside enantiomer (xe2x88x92) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (xe2x80x9cFTCxe2x80x9d) exhibits significant activity against HIV (EC50 of 0.0077 to 0.02 xcexcM), HBV (hepatitis B virus), and other viruses replicating in a similar manner. The (+)-enantiomer of FTC is also active against HIV (EC50 of 0.28-0.84 xcexcM).
USPTO Backgrounds
USPTO Backgrounds